STAT Plus: Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug
Hello, everyone, and how are you today? We are doing just fine, thank you, despite a long evening trek to visit the home office. Thanks to a cup or two of stimulation, we are motoring along, as usual. And we invite you to do the same. After all, the neurons can use as much as you can offer, yes? So on that note, time to get cracking. Here are some tidbits to get you started. We hope your journey today is successful and you conquer the world. And please do keep us in mind if something saucy pops up. …
Unity Biotechnology (UBX), a biotech focused on developing drugs that address what it says is a fundamental mechanism of aging, released the first human data on its first experimental drug, a treatment for osteoarthritis, STAT explains. The data represent the first test in humans of some tantalizing basic science showing that killing old, or senescent, cells that collect in the body may reduce some symptoms of aging. The results are more promising than the expectations set by Unity and Wall Street analysts, many of whom did not expect any benefit at all on patient symptoms.
Continue to STAT Plus to read the full story…
